The role of chemokines in Schistosoma mansoni infection: Insights from human disease and murine models

Memorias do Instituto Oswaldo Cruz

Volumn 101, Issue SUPPL. 1, 2006, Pages 333-338

  Souza, Adriano L S ^a   Sousa Pereira, Silvio R ^b   Teixeira, Mauro M ^a   Lambertucci, José R ^b   Teixeira, Antonio L ^b  

^a Instituto de Ciencias Biologicas   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Chemokines; Inflammation; Schistosomiasis

Indexed keywords

MURINAE; MUS; SCHISTOSOMA MANSONI;

EID: 33846457411     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762006000900054     Document Type: Conference Paper

References (42)

1. Bao L, Zhu Y, Zhu J, Lindgren JU 2005. Decreased IgG production but increased MIP-1beta expression in collagen-induced arthritis in C-C chemokine receptor 5-deficient mice. Cytokine 31: 64-71.
2. Booth M, Mwatha JK, Joseph S, Jones FM, Kadzo H, Ireri E, Kazibwe F, Kemijumbi J, Kariuki C, Kimani G, Ouma JH, Kabatereine NB, Vennervald BJ, Dunne DW 2004. Periportal fibrosis in human Schistosoma mansoni infection is associated with low IL-10, low IFN-gamma, high TNFalpha, or low RANTES, depending on age and gender. J Immunol 172: 1295-303.
3. Charo IF, Ransohoff RM 2006. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354: 610-621.
4. Chensue SW, Warmington KS, Allenspach EJ, Lu B, Gerard C, Kunkel SL, Lukacs NW 1999. Differential expression and cross-regulatory function of RANTES during mycobacterial (type 1) and schistosomal (type 2) antigen-elicited granulomatous inflammation. J Immunol 163: 165-73.
5. Chensue, SW, Lukacs NW, Yang TY, Shang X, Frait KA, Kunkel SL, Kung T, Wiekowski MT, Hedrick JA, Cook DN, Zingoni A, Narula SK, Zlotnik A, Barrat FJ, O'Garra A, Napolitano M, Lira SA 2001. Aberrant in vivo T helper type 2 cell response and impaired eosinophil recruitment in CC chemokine receptor 8 knockout mice. J Exp Med 193: 573-584.
6. Falcão PL, Correa-Oliveira R, Fraga LAO, Talvani A, Proudfoot AE, Wells TNC, Williams TJ, Jose PJ, Teixeira MM 2002. Plasma concentrations and role of macrophage inflammatory protein-1a (MIP-1a/CCL3) during chronic Schistosoma mansoni infection in humans. J Infect Dis 186: 1696-1700.
7. Fallon PG 2000. Immunopathology of schistosomiasis: a cautionary tale of mice and men. Immunol Today 21: 29-35.
8. Gao JL, Wynn, TA, Chang Y, Lee EJ, Broxmeyer HE, Cooper S, Tiffany HL, Wespahl H, Kwon-Chung J, Murphy PM 1997. Impaired host defense, hematopoiesis, granulomatous inflammation, and type 1-type2, cytokine balance in mice lacking CC chemokine receptor 1. J Exp Med 185: 1959-1968.
9. Gerard C, Rollins BJ 2001. Chemokines and disease. Nat Immunol 2: 108-115.
10. Johnson Z, Power CA, Weiss C, Rintelen F, Ji H, Ruckle T, Camps M, Wells TN, Schwarz MK, Proudfoot AE, Rommel C 2004. Chemokine inhibition-why, when, where, which and how? Biochem Soc Trans 32: 366-377.
11. Lukacs NW, Chensue SW, Smith RE, Strieter RM, Warmington K, Wilke C, Kunkel SL 1994a. Production of monocyte chemoattractant protein-1 and macrophage inflammatory protein-1 alpha by inflammatory granuloma fibroblasts. Am J Pathol 144: 711-718.
12. Lukacs NW, Kunkel SL, Strieter RM, Warmington K, Chensue, SW 1993. The role of macrophage inflammatory protein-1 alpha in Schistosoma mansoni egg-induced granulomatous inflammation. J Exp Med 177: 1551-1559.
13. Lukacs NW, Strieter RM, Shaklee CL, Chensue SW, Kunkel SL 1994b. Macrophage inflammatory protein-1α-/- influences eosinophil recruitment in antigen-specific airway inflammation. Eur J Immunol, 25: 245-251.
14. Machado FS, Koyama NS, Carregaro V, Ferreira BR, Milanezi CM, Teixeira MM, Rossi MA, Silva JS 2005. CCR5 plays a critical role in the development of myocarditis and host protection in mice infected with Trypanosoma cruzi. J Infect Dis 191: 627-636.
15. Mackay CR 2001. Chemokines: immunology's high impact factors. Nat Immunol 2: 95-101.
16. Maurer M, Von Stebut E 2004. Macrophage inflammatory protein-1. Int J Biochem Cell Biol 36: 1882-1886.
17. Menten P, Wuyts A, Van Dame J 2002. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev 13: 455-481.
18. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, Miller LH, Oppeinheim JJ, Power CA 2000. International Union of Pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52: 145-176.
19. Nibbs RJ, Wylie SM, Pragnell IB, Graham GJ 1997. Cloning and characterization of a novel murine beta chemokine receptor, D6. Comparison to three other related macrophage inflammatory protein-1alpha receptors, CCR-1, CCR-3, and CCR-5. J Biol Chem 272: 12495-12504.
20. Nobre V, Silva LC, Ribas JG, Rayes A, Serufo JC, Lana-Peixoto MA, Marinho RF, Lambertucci JR 2001. Schistosomal myeloradiculopathy due to Schistosoma mansoni: report on 23 cases. Mem Inst Oswaldo Cruz 96: 137-141.
21. Oliveira DM, Silva-Teixeira DN, Goes AM 1999. Evidence for nitric oxide action on in vitro granuloma formation through pivotal changes in MIP-1a and IL-10 release in human schistosomiasis. Nitric Oxide 6: 162-171.
22. Olson TS, Ley K 2002. Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol 283: R7-28.
23. Post TW, Bozic CR, Rothenberg ME, Luster AD, Gerard N, Gerard C 1995. Molecular characterization of two murine eosinophil beta chemokine receptors. J Immunol 155: 5299-5305.
24. Proudfoot AE 2002. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2: 106-115.
25. Proudfoot AE, Power CA, Rommel C, Wells TN 2003. Strategies for chemokine antagonists as therapeutics. Sem Immunol 15: 57-65.
26. Proudfoot AE, Power CA, Wells TN 2000. The strategy of blocking the chemokine system to combat disease. Immunol Rev 177: 246-256.
27. Qiu B, Frait KA, Reich F, Komuniecki E, Chensue SW 2001. Chemokine expression dynamics in mycobacterial (type 1) and schistosomal (type 2) antigen-elicited granulomatous inflammation. Am J Pathol 158: 1503-1515.
28. Ritz SA, Cundall MJ, Gajewska BU, Swirski FK, Wiley RE, Alvarez D, Coyle AJ, Stampfli MR, Jordana M 2004. The lung cytokine microenvironment influences molecular events in the lymph nodes during Th1 and Th2 respiratory mucosal sensitization to antigen in vivo. Clin Exp Immunol 138: 213-220.
29. Rutitzky LI, Hernandez HJ, Stadecker MJ 2001. Th1-polarizing immunization with egg antigens correlates with severe exacerbation of immunopathology and death in schistosome infection. Proc Natl Acad Sci USA 98: 13243-13248.
30. Rutitzky LI, Lopes RJR, Stadecker MJ 2005. Severe CD4 T Cell-Mediated immunopathology in murine schistosomiasis is dependent on IL-12p40 and correlates with high levels of IL-17. J Immunol 175: 3920-3926.
31. Schrum S, Probst P, Fleischer B, Zipfel PF 1996. Synthesis of the CC-chemokines MIP-1α, MIP-1β, and RANTES is associated with a type 1 immune response. J Immunol 157: 3598-3604.
32. Silva LC, Maciel PE, Ribas JG, Souza-Pereira SR, Serufo JC, Andrade LM, Antunes CM, Lambertucci JR 2004. Schistosomal myeloradiculopathy. Rev Soc Bras Med Trop 37: 261-272.
33. Siveke JT, Hamann AT 1998. T helper 1 and T helper 2 cells respond differentially to chemokines. J Immunol 160: 550-554.
34. Sousa-Pereira S, Teixeira AL, Silva LC, Souza AL, Antunes CM, Teixeira MM, Lambertucci JR 2006. Serum and cerebral spinal fluid levels of chemokines and Th2 cytokines in Schistosoma mansoni myeloradiculopathy. Parasite Immunol (in press).
35. Souza AL 2005. Papel de MIP-1 a/CCL3 e do receptor CCR5 na infecção por Schistosoma mansoni, Thesis, Universidade Federal de Minas Gerais, Belo Horizonte, 144 pp.
36. Souza AL, Roffê E, Pinho V, Souza DG, Silva AF, Russo RC, Guabiraba R, Pereira CA, Carvalho FM, Barsante MM, Corrêa-Oliveira R, Fraga LA, Negrão-Corrêa D, Teixeira MM 2005. Potential role of the chemokine macrophage inflammatory protein 1alpha in human and experimental schistosomiasis. Infect Immun 73: 2515-2523.
37. Stadecker MJ, Asahi H, Finger E, Hernandez HJ, Rutitzky LI, Sun J 2004. The immunobiology of Th1 polarization in high-pathology schistosomiasis. Immunol Rev 201: 168-179.
38. Vennervald BJ, Dunne DW 2004. Morbidity in schistosomiasis: an update. Curr Opin Infect Dis 17: 439-447.
39. Vierboom MP, Zavodny PJ, Chou CC, Tagat JR, Pugliese-Sivo C, Stritzki J, Steensma RW, McCombie SW, Celebi-Paul L, Remarque E, Jonker M, Narula SK, Hart B 2005. Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5. Arthritis Rheum 52: 627-636.
40. Warmington KS, Boring L, Ruth JH, Sonstein J, Hogaboam CM, Curtis JL, Kunkel SL, Charo IR, Chensue SW 1999. Effect of C-C chemokine receptor 2 (CCR2) knockout on type-2 (schistosomal antigen elicited) pulmonary granuloma formation: analysis of cellular recruitment and cytokine responses. Am J Pathol 154: 1407-1416.
41. Welniak LA, Wang Z, Sun K, Kuziel W, Anver MR, Blazar BR, Murphy WJ 2004. An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease. Exp Hematol 32: 318-324.
42. Zhou Y, Kurihara T, Ryseck RP, Yang Y, Ryan C, Loy J, Warr G, Bravo R 1998. Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J Immunol 160: 4018-4025.